Cooperation with GLG Pharma S.A


Contact


News

Archive News


Pharmaceutical Research Institute and GLG Pharma S.A (Polish subsidiary of GLG LLC, Boston, USA) have signed a cooperation agreement within the TNBC Project realized under INNOMED funding and partially refunded by the National Centre for Research and Development.

The TNBC Project – the flagship project of GLG LLC – concerns the development of a targeted therapy for treating triple negative breast cancer (TNBC) based on innovative STAT-3 protein inhibitors, i.e. GLG-805 and GLG-302 particles. GLG Pharma owns an exclusive global licence to develop, manufacture and market pharmaceutical products based on the above mentioned technology. GLG Pharma is also elaborating a series of innovative particles that could be applied in treating various types of cancers and kidney conditions.

The task of Pharmaceutical Research Institute will consist in developing the synthesis of GLG-805, GMP technology upscaling, elaborating analytical methods, stability testing and preparing appropriate registration documentation for the API. Suitable patent applications will be drafted for the intravenous and/or oral drug form also developed in the Institute. Then the obtained GLG-805 substance will be used in preclinical animal trials and clinical trials.

All the works carried out in Pharmaceutical Research Institute will be part of the project called “Development of a targeted therapy for treating triple negative breast cancer based on innovative STAT-3 protein inhibitors, i.e. GLG-805 or GLG-302 particles, and elaboration of diagnostic tests based on immunochemical methods for swift diagnostics of a TNBC cancer caused by the presence of the activated STAT-3 protein, including the attempts at monitoring protein concentration in response to the therapy employing GLG-805 or GLG-302 particles”. The project is planned for the years 2014-2020 and co-financed from the funds of the European Regional Development Fund.